Plain-English translation of NCT06636786 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether (TNX-102 SL), a medication taken under the tongue at bedtime, can help prevent acute stress reactions and post-traumatic stress disorder (PTSD) in people who have recently experienced a traumatic event like a motor vehicle accident. The medication has been studied in over 1,100 people so far and has shown promise in improving sleep quality, which research suggests plays an important role in how people recover from trauma.
After traumatic events like car accidents, many people develop acute stress reactions and PTSD, which can significantly impact their work performance and quality of life. Researchers believe that taking this medication early after a traumatic event—especially because it improves sleep—might help prevent these long-term stress problems from developing.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take either the active medication or a placebo (dummy pill) sublingually—meaning it dissolves under your tongue—starting in the emergency department and continuing at bedtime for 14 days total. You will receive either 28 or 29 tablets depending on when you start. Throughout the study, you will complete check-ins via your smartphone and email to track how you're doing, and researchers will monitor your stress symptoms and overall recovery over the study period.
AI-generated summary from trial data · Sep 15, 2026 · Not medical advice
United States